At the end of the latest market close, Travere Therapeutics Inc. (TVTX) was valued at $18.90. In that particular session, Stock kicked-off at the price of $18.79 while reaching the peak value of $18.905 and lowest value recorded on the day was $16.66. The stock current value is $18.27.
Recently in News on May 6, 2021, Travere Therapeutics Reports First Quarter 2021 Financial Results. Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21. You can read further details here
Travere Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $33.09 on 02/02/21, with the lowest value was $16.66 for the same time period, recorded on 05/14/21.
Travere Therapeutics Inc. (TVTX) full year performance was 20.12%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Travere Therapeutics Inc. shares are logging -44.79% during the 52-week period from high price, and 26.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $14.50 and $33.09.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2520412 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Travere Therapeutics Inc. (TVTX) recorded performance in the market was -32.97%, having the revenues showcasing -30.74% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.14B, as it employees total of 262 workers.
The Analysts eye on Travere Therapeutics Inc. (TVTX)
During the last month, 0 analysts gave the Travere Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 26.47, with a change in the price was noted -9.24. In a similar fashion, Travere Therapeutics Inc. posted a movement of -33.59% for the period of last 100 days, recording 582,515 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TVTX is recording 0.60 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.60.
Technical rundown of Travere Therapeutics Inc. (TVTX)
Raw Stochastic average of Travere Therapeutics Inc. in the period of last 50 days is set at 12.71%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 17.37%. In the last 20 days, the company’s Stochastic %K was 10.54% and its Stochastic %D was recorded 10.56%.
Considering, the past performance of Travere Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -32.97%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -23.87%, alongside a boost of 20.12% for the period of the last 12 months. The shares increased approximately by -8.70% in the 7-day charts and went up by -29.57% in the period of the last 30 days. Common stock shares were lifted by -30.74% during last recorded quarter.